Literature DB >> 16292589

Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.

Lieuwe de Haan1, Jan Booij, Jules Lavalaye, Therese van Amelsvoort, Don Linszen.   

Abstract

RATIONALE: Occupancy of dopamine D2 receptors by antipsychotic drugs depends on the individual availability of D2 receptors and on the dose and type of antipsychotic medication. It has been suggested that a low availability of these receptors may increase the risk for addictive behavior.
OBJECTIVE: This study aims to show that patients with relatively high occupancy of D2 receptors by antipsychotic drugs are more prone to nicotine consumption.
METHODS: Striatal D2 receptor occupancy by equivalent doses of olanzapine or risperidone was assessed with [123I]iodobenzamide single-photon emission computed tomography (SPECT) in 36 patients with schizophrenia. Smoking status at the time of SPECT imaging was assessed. The number of cigarettes used in the following three consecutive years was estimated with the Life Chart Schedule (LCS).
RESULTS: There was a positive and significant relation between D2 receptor occupancy following treatment with olanzapine (n=19) or risperidone (n=12) and the number of cigarettes smoked in three consecutive years (r=0.60, p<0.001) in patients who smoked. There was a significant difference in the percentage of D2 occupancy for smokers (mean 74.3%, SD 12.8, n=31) and nonsmokers (mean 49.8%, SD 9.1, n=5).
CONCLUSION: Frequency of cigarette smoking in schizophrenic patients treated with antipsychotic medication is significantly and negatively related to the availability of striatal D2 receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16292589     DOI: 10.1007/s00213-005-0218-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Reliability of the life chart schedule for assessment of the long-term course of schizophrenia.

Authors:  E Susser; M Finnerty; R Mojtabai; S Yale; S Conover; R Goetz; X Amador
Journal:  Schizophr Res       Date:  2000-03-16       Impact factor: 4.939

2.  Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.

Authors:  L de Haan; J Lavalaye; D Linszen; P M Dingemans; J Booij
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

3.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.

Authors:  N P Verhoeff; O Kapucu; E Sokole-Busemann; E A van Royen; A G Janssen
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

5.  Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels.

Authors:  N D Volkow; G J Wang; J S Fowler; J Logan; S J Gatley; A Gifford; R Hitzemann; Y S Ding; N Pappas
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

6.  A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.

Authors:  Jose de Leon; Francisco J Diaz
Journal:  Schizophr Res       Date:  2005-07-15       Impact factor: 4.939

7.  Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.

Authors:  G E Swan; A M Valdes; H Z Ring; T V Khroyan; L M Jack; C C Ton; S J Curry; T McAfee
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

Review 8.  Dopamine in drug abuse and addiction: results from imaging studies and treatment implications.

Authors:  N D Volkow; J S Fowler; G-J Wang; J M Swanson
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

9.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.

Authors:  T Pohjalainen; J O Rinne; K Någren; P Lehikoinen; K Anttila; E K Syvälahti; J Hietala
Journal:  Mol Psychiatry       Date:  1998-05       Impact factor: 15.992

View more
  5 in total

Review 1.  Smoking in schizophrenic patients: A critique of the self-medication hypothesis.

Authors:  Francesca Manzella; Susan E Maloney; George T Taylor
Journal:  World J Psychiatry       Date:  2015-03-22

2.  Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia.

Authors:  Alexis E Whitton; Alan I Green; Diego A Pizzagalli; Robert M Roth; Jill M Williams; Mary F Brunette
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 3.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 4.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 5.  Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.